Sponsor or institution

Clinical trials and research at Genentech, Inc.

• 16Clinical trials
• 21Countries

Newest trials

All recruiting trials (16)

• See if RO7965032 helps geographic atrophy from AMD

  This trial tests RO7965032 versus placebo to see if it can help people with geographic atrophy due to age-related macular degeneration.

  Recruiting at 5 sites Phase 2 Genentech, Inc. · Walnut Creek, California and 4 other locations · NCT07851259

• Testing RO7890597 safety and how it moves through the body in healthy adults

  This study tests RO7890597 against placebo in healthy adults to see its safety, how it behaves in the body, and any activity at different doses.

  Recruiting Phase 1 Genentech, Inc. · Lenexa, Kansas · NCT07797478

• Cevostamab in systemic lupus erythematosus with or without active lupus nephritis

  This study tests cevostamab in people with systemic lupus erythematosus, with or without active lupus nephritis, to see how safe it is and how the body handles it when added to standard care.

  Recruiting at 11 sites Phase 1 Genentech, Inc. · Parkville, Victoria and 10 other locations · NCT07629583

• Ocrelizumab given under the skin after switching from another anti-CD20 therapy

  This study tests a subcutaneous form of ocrelizumab mixed with rHuPH20 in people with relapsing or primary progressive MS who are switching from another anti-CD20 treatment.

  Recruiting at 8 sites Phase 4 Genentech, Inc. · Birmingham, Alabama and 7 other locations · NCT07609719

• GDC-1261 in advanced or metastatic prostate cancer

  This study tests GDC-1261 to see if it is safe and how it behaves in people with advanced or metastatic prostate cancer who have progressed on prior therapy.

  Recruiting at 6 sites Phase 1/2 Genentech, Inc. · Scottsdale, Arizona and 5 other locations · NCT07567846

• RO7851624 in relapsed/refractory multiple myeloma (RRMM)

  This early-phase study tests RO7851624 in people with RRMM who have exhausted standard treatments.

  Recruiting at 2 sites Phase 1 Genentech, Inc. · Parkville, Victoria and 1 other locations · NCT07558915

• Giredestrant after aromatase inhibitor intolerance in early ER+/HER2- breast cancer

  This study tests switching to giredestrant for postmenopausal women with ER+/HER2- early breast cancer who had AI intolerance, to see if it’s tolerable and can improve patient-reported outcomes.

  Recruiting at 8 sites Phase 3 Genentech, Inc. · Fountain Valley, California and 7 other locations · NCT07541079

• Selnoflast to reduce artery inflammation in people with atherosclerosis at high risk of heart events

  This study will test whether selnoflast can lower artery inflammation in people with atherosclerosis who are at high risk for major heart problems and are already on standard treatments.

  Recruiting at 25 sites Phase 2 Genentech, Inc. · Beverly Hills, California and 24 other locations · NCT07448038

• RO7823653 injections, alone or with faricimab, for diabetic macular edema

  This research tests injections of RO7823653, given alone or with faricimab, in people with diabetic macular edema to see if the medication is safe and how the eye handles it.

  Recruiting at 12 sites Phase 1 Genentech, Inc. · Peoria, Arizona and 11 other locations · NCT07425522

• GDC-4198 alone and with giredestrant versus abemaciclib plus giredestrant for advanced ER+, HER2- breast cancer

  This study will test whether the new drug GDC-4198, alone or with giredestrant, works better or is as safe as abemaciclib plus giredestrant for people with advanced or metastatic ER-positive, HER2-negative breast cancer who progressed after CDK4/6 inhibitors.

  Recruiting at 77 sites Phase 1/2 Genentech, Inc. · Huntsville, Alabama and 76 other locations · NCT07100106

• RO7837195 for moderate to severe ulcerative colitis after other treatments failed

  This 12-week test will see if the experimental drug RO7837195 helps people with moderate to severe ulcerative colitis whose prior conventional or advanced treatments did not work or caused intolerable side effects.

  Recruiting at 106 sites Phase 2 Genentech, Inc. · Lancaster, California and 110 other locations · NCT06979336

• Evaluating GDC-7035 for advanced solid tumors with KRAS G12D mutation

  This study is testing a new drug called GDC-7035 to see if it can help people with advanced solid tumors that have a specific KRAS G12D mutation, either on its own or with other cancer treatments.

  Recruiting at 48 sites Phase 1 Genentech, Inc. · La Jolla, California and 48 other locations · NCT06619587

• Evaluating a new combination treatment for relapsed or refractory multiple myeloma

  This study is testing a new combination of two treatments for people with relapsed or refractory multiple myeloma to see if it's safe and how well it works.

  Recruiting at 14 sites Phase 1 Genentech, Inc. · Camperdown, New South Wales and 13 other locations · NCT05927571

• Evaluating a new treatment for advanced prostate cancer

  This study is testing a new treatment for advanced prostate cancer to see how safe it is and if it helps patients feel better.

  Recruiting at 26 sites Phase 1 Genentech, Inc. · Scottsdale, Arizona and 25 other locations · NCT05800665

• Optimizing surgical delivery of OpRegen for geographic atrophy in AMD patients

  This study is testing a new surgical method to deliver OpRegen to see if it can help people with geographic atrophy from age-related macular degeneration improve their vision safely.

  Recruiting at 17 sites Phase 2 Genentech, Inc. · Beverly Hills, California and 16 other locations · NCT05626114

• Cevostamab in relapsed or refractory multiple myeloma

  This early-stage trial tests cevostamab alone or with standard therapies to see if it is safe and how it behaves in people with relapsed or refractory multiple myeloma.

  Recruiting at 4 sites Phase 1 Genentech, Inc. · Duarte, California and 33 other locations · NCT04910568

Quick answers

How many clinical trials run by Genentech, Inc. are recruiting right now?

16, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 21 countries. The most sites are in United States (13 trials), Australia (9 trials), South Korea (7 trials), Canada (6 trials), France (6 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 8, Phase 2: 4, Phase 1/2: 2, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →